“so I would say more to come in the next couple quarters, but we remain positive about where we stand at this point with CVS CostVantage and how it’s resonating in the marketplace.”

In context

“rem and the team have been working with PBMs to really contract and address those pharmacy reimbursements and have had success, as I mentioned in my prepared remarks - we have eight PBM contracts already signed and underway. I’ll let Prem talk more specifically about those contracts and where we’re headed. Prem Shah: Yes, appreciate the question, Ann. Look - we continue to have active, productive discussions with our large PBM partners and continue to make progress in transitioning all of our commercial contracts for January 1, 2025. At the end of the day, if you think about the retail pharmacy reimbursement landscape and how it works, what we’re doing with CVS CostVantage allows pharmacies to be reasonably compensated for the care and the value that they provide in the local communities, so I would say more to come in the next couple quarters, but we remain positive about where we stand at this point with CVS CostVantage and how it’s resonating in the marketplace. Operator: The next question comes from Eric Percher from Nephron Research. Eric, your line is open, please go ahead. Eric Percher: Thank you. I’d like to ask for a little bit more on the Part D marketplace, given the initial bid direct subsidy exposure and the demo program. Can you give us an idea for your response to that program, does the Part D demo help to de-risk this marketplace? Karen Lynch: Eric, we’re really pleased that CMS has offered this Part D program to really stabilize the Part D premium. We have applied for the demonstration and are looking forward to working out the details, but we really do think that this was the right answer and we’re very pleased. We were talking with CMS over the course of the last several months, we felt like we had influence over that and feel goo”